As early as 1984, the first generation of mTOR inhibitor, rapamycin, was tried for tumor treatment (Eng et al. 1984), and subsequent reports suggested that the combined use of rapamycin and other drugs had great antitumor effect (Bae-Jump et al. 2009; Han et al. 2012; Shafer et al. 2010; Kimura and Huang 2016). Here, MTOR is linked to neoplasm.